📊 CYRX Key Takeaways
Is Cryoport, Inc. (CYRX) a Good Investment?
Cryoport exhibits deteriorating operational fundamentals with flat revenue growth (0% YoY) and persistent operating losses (-20.1% margin), resulting in negative free cash flow (-$6.2M) despite a strong balance sheet. The company cannot cover interest expenses and is burning capital, suggesting urgent need for margin expansion and revenue acceleration to justify continued operation.
Cryoport’s balance sheet is solid, with substantial cash, good liquidity, and modest leverage, but the core business remains fundamentally weak. Revenue is flat, operating margins are deeply negative, and both operating cash flow and free cash flow are negative, which suggests the strong net income and EPS likely do not reflect durable operating performance.
Why Buy Cryoport, Inc. Stock? CYRX Key Strengths
- Strong cash position of $272.9M provides operational runway
- Solid gross margin of 45.8% indicates core product economics are viable
- Conservative balance sheet with 0.23x debt-to-equity and 2.09x current ratio
- Strong liquidity with $250.49M in cash and current ratio of 2.17x
- Low balance-sheet leverage with debt/equity of 0.23x
- Healthy gross margin of 47.1%, indicating the underlying service mix still has economic potential
CYRX Stock Risks: Cryoport, Inc. Investment Risks
- Zero revenue growth indicates market stagnation or competitive displacement
- Negative free cash flow of -$6.2M unsustainable without balance sheet deterioration
- Operating losses of -$9.6M with negative interest coverage ratio suggests inability to meet debt obligations
- High capex ($10.0M) relative to operating cash flow ($3.7M) creates structural cash burn
- Operating losses remain significant with a -20.9% operating margin
- Cash generation is weak, with negative operating cash flow and -$25.02M free cash flow
- Revenue growth is stalled, raising concerns about the quality and sustainability of earnings
Key Metrics to Watch
- Revenue growth acceleration and quarterly trends
- Operating margin improvement and path to profitability
- Free cash flow sustainability and cash burn rate
- Capex intensity reduction or return on capital deployed
- Operating margin and operating cash flow
- Revenue growth and free cash flow trend
Cryoport, Inc. (CYRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.09x current ratio provides a solid financial cushion.
CYRX Profit Margin, ROE & Profitability Analysis
CYRX vs Healthcare Sector: How Cryoport, Inc. Compares
How Cryoport, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cryoport, Inc. Stock Overvalued? CYRX Valuation Analysis 2026
Based on fundamental analysis, Cryoport, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cryoport, Inc. Balance Sheet: CYRX Debt, Cash & Liquidity
CYRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cryoport, Inc.'s revenue has declined by 26% over the 5-year period, indicating business contraction. The most recent EPS of $-2.21 indicates the company is currently unprofitable.
CYRX Revenue Growth, EPS Growth & YoY Performance
CYRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $41.0M | -$10.5M | $-0.25 |
| Q3 2025 | $38.3M | $805.0K | $-0.02 |
| Q2 2025 | $39.7M | -$78.0M | $-1.62 |
| Q1 2025 | $37.3M | -$12.0M | $-0.28 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cryoport, Inc. Dividends, Buybacks & Capital Allocation
CYRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cryoport, Inc. (CIK: 0001124524)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CYRX
What is the AI rating for CYRX?
Cryoport, Inc. (CYRX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 77% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CYRX's key strengths?
Claude: Strong cash position of $272.9M provides operational runway. Solid gross margin of 45.8% indicates core product economics are viable. ChatGPT: Strong liquidity with $250.49M in cash and current ratio of 2.17x. Low balance-sheet leverage with debt/equity of 0.23x.
What are the risks of investing in CYRX?
Claude: Zero revenue growth indicates market stagnation or competitive displacement. Negative free cash flow of -$6.2M unsustainable without balance sheet deterioration. ChatGPT: Operating losses remain significant with a -20.9% operating margin. Cash generation is weak, with negative operating cash flow and -$25.02M free cash flow.
What is CYRX's revenue and growth?
Cryoport, Inc. reported revenue of $47.8M.
Does CYRX pay dividends?
Cryoport, Inc. does not currently pay dividends.
Where can I find CYRX SEC filings?
Official SEC filings for Cryoport, Inc. (CIK: 0001124524) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CYRX's EPS?
Cryoport, Inc. has a diluted EPS of $-0.25.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CYRX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Cryoport, Inc. has a SELL rating with 77% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CYRX stock overvalued or undervalued?
Valuation metrics for CYRX: ROE of -2.1% (sector avg: 15%), net margin of -22.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CYRX stock in 2026?
Our dual AI analysis gives Cryoport, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CYRX's free cash flow?
Cryoport, Inc.'s operating cash flow is $3.7M, with capital expenditures of $10.0M. FCF margin is -13.1%.
How does CYRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -22.1% (avg: 12%), ROE -2.1% (avg: 15%), current ratio 2.09 (avg: 2).